Komori
Daito Pharmaceutical (4577) · RiskMaterialisedLatest Earnings (2026-10-14): "Restated"

Risk of fluctuations in raw-material and procurement prices

First written in FY2016. 14 of 23 entries say "Materialised", first in FY2023-Q1. Latest entry: 2026-10-14.

23entries
11years
8from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2018MitigatedFY2020MaterialisedFY2022 – 2026-07-102016: 12017: 120172018: 120182019: 020192020: 120202021: 020212022: 220222023: 420232024: 220242025: 220252026: 92026
Same theme, other companies
Impact of Raw Material Price Fluctuations on EarningsA theme 65 companies write about · 57 as a headwind · 5 as a tailwind

Daito Pharmaceutical moved to the "Worse" side of this theme in 2022, 4 years after the typical company in this theme (2018).

The whole theme swung hardest in 2022: 40 of 57 companies on the "Worse" side.

17 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 65 companies compared. The sentences above are computed from all 65.
Full recordFilings, disclosures and news, newest first
  1. FY2026MaterialisedAnnual report

    「Cost of sales for the current consolidated fiscal year was ¥40,753 million. This reflected higher depreciation and amortisation, soaring raw material costs due to escalating tensions in the Middle East and the weaker yen, and investment in human capital, despite the elimination of inventory valuation losses through reductions in long-outstanding inventory and the thorough implementation of smart spending.」

    Soaring raw material costs due to escalating tensions in the Middle East and the weaker yen were reflected in cost of sales for the current fiscal year, and the risk of fluctuations in raw material prices continues to be disclosed.
  2. FY2025MaterialisedAnnual report

    「Cost of sales for the current consolidated fiscal year was ¥42,005 million, affected by changes in the product mix, higher depreciation and amortisation, inventory write-downs, and soaring raw material costs due to the weaker yen.」

    Soaring raw material costs due to the weaker yen emerged in full-year results as a factor behind higher cost of sales, and operating profit declined 32.7% year on year.
  3. FY2025-H1MaterialisedAnnual report

    「Although revenue increased, operating profit was ¥1,471 million, down 35.7% year on year, ordinary profit was ¥1,470 million, down 36.5%, and interim profit attributable to owners of the parent was ¥908 million, down 41.5%, mainly due to higher depreciation and amortisation, the impact of inventory valuation, and higher raw material costs resulting from higher raw material prices driven by the weaker yen.」

    Higher raw material prices, driven by the weaker yen, emerged as an increase in raw material costs, leading to declines in operating profit and other income items while revenue increased.
  4. FY2024MaterialisedAnnual report

    「Although profit increased in line with the rise in revenue, operating profit was ¥3,894 million, down 25.2% year on year, ordinary profit was ¥3,923 million, down 24.1%, and profit attributable to owners of the parent was ¥3,295 million, down 8.5%, mainly due to higher raw material costs resulting from the weaker yen and increased research and development expenses.」

    It states that higher raw material costs resulting from the weaker yen emerged as a decline in full-year profit, with operating profit, ordinary profit and net profit declining year on year.
  5. FY2024-Q2MaterialisedAnnual report

    「As a result, revenue for the six months ended the second quarter of the current consolidated fiscal year was ¥24,110 million, up 3.2% year on year. Although revenue increased, operating profit was ¥2,289 million, down 19.0% year on year, ordinary profit was ¥2,314 million, down 15.9%, and profit attributable to owners of the parent was ¥1,552 million, down 11.9%, mainly due to higher raw material costs and increased research and development expenses.」

    It states that higher raw material costs resulting from higher raw material prices, driven by the weaker yen, were reflected in the results, while revenue increased and operating profit, ordinary profit and profit attributable to owners of the parent declined year on year.
  6. FY2024-Q1MaterialisedAnnual report

    「Although revenue increased, operating profit was ¥1,080 million, down 28.0% year on year, ordinary profit was ¥1,092 million, down 26.0%, and profit attributable to owners of the parent was ¥683 million, down 27.7%, mainly due to higher raw material costs resulting from higher raw material prices, primarily because of the weaker yen, as well as increased research and development expenses.」

    It states that higher raw material prices, driven by the weaker yen, emerged as an increase in raw material costs, leading to declines in operating profit, ordinary profit and profit attributable to owners of the parent.
  7. FY2023MaterialisedAnnual report

    「Although higher revenue led to higher profit, operating profit fell 20.5% year on year to ¥5,207 million, ordinary profit fell 23.2% to ¥5,169 million, and profit attributable to owners of the parent fell 22.9% to ¥3,600 million, mainly due to increases in raw-material costs and electricity charges resulting from the weaker yen and higher energy prices, as well as increases in depreciation expense and research and development expenses.」

    It states that higher raw material costs, electricity charges and other expenses resulting from the weaker yen and rising energy resource prices emerged as a decline in full-year profit.
  8. FY2023-Q3MaterialisedAnnual report

    「Although higher revenue led to higher profit, operating profit fell 27.3% year on year to ¥5,207 million, ordinary profit fell 23.2% to ¥5,169 million, and profit attributable to owners of the parent fell 22.9% to ¥3,600 million, mainly due to increases in raw-material costs and electricity charges resulting from the weaker yen and higher energy prices, as well as increases in depreciation expense and research and development expenses.」

    It states that the weaker yen and higher energy prices continued to appear in the results as increases in raw-material costs, electricity charges and other expenses, leading to declines in operating profit and other earnings.
  9. FY2023-Q2MaterialisedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, the Japanese economy remained uncertain, as the impact of the COVID-19 pandemic continued and rising energy and raw-material prices due to the prolonged situation in Ukraine and the rapid depreciation of the yen continued to weigh on the outlook. As a result, revenue for the cumulative second quarter of the current consolidated fiscal year was ¥23,367 million, up 4.0% year on year. Although higher revenue led to higher profit, operating profit fell 27.1% year on year to ¥2,826 million, mainly due to increases in raw-material costs and electricity charges resulting from the weaker yen and higher energy prices, as well as increases in depreciation expense and research and development expenses.」

    The weaker yen and higher energy prices appeared in the results as increases in raw-material costs, electricity charges and other expenses, and operating profit fell 27.1% year on year.
  10. FY2023-Q1MaterialisedAnnual report

    「During the cumulative first quarter of the current consolidated fiscal year, the Japanese economy remained uncertain, as the impact of the COVID-19 pandemic continued and concerns arose over rising energy and raw-material prices due to escalating tensions surrounding Ukraine and the rapid depreciation of the yen. Although higher revenue led to higher profit, operating profit fell 36.4% year on year to ¥1,501 million, mainly due to higher raw-material costs resulting from the weaker yen, as well as increases in depreciation expense and research and development expenses.」

    It states that rising raw-material prices driven by the situation in Ukraine and the rapid depreciation of the yen appeared in the results as higher raw-material costs and a 36.4% year-on-year decline in operating profit.
  11. FY2022WorsenedAnnual report

    「At the same time, concerns remain about the impact of rising energy and raw-material prices due to escalating tensions surrounding Ukraine, and the outlook remains uncertain.」

    Regarding raw-material price fluctuation risk, it identifies rising energy and raw-material prices due to escalating tensions surrounding Ukraine as a new concern in addition to exchange rates and other existing factors.
  12. FY2020MitigatedAnnual report

    「To address these risks, the Group hedges to a certain extent the foreign-exchange risk associated with foreign-currency transactions through forward foreign-exchange contracts and other instruments.」

    As measures addressing raw-material and procurement price risk and foreign-exchange risk, it specifies hedging through forward foreign-exchange contracts and other instruments.
  13. FY2018RestatedAnnual report

    「If the prices of raw materials used in the manufacture and sale of the Group's APIs and formulations, or of APIs and other products procured for resale, fluctuate sharply due to exchange rates or other factors, the Group's business performance and financial position may be affected.」

    Reiterates the risk of sharp fluctuations in raw-material and procurement prices and exchange rates.
  14. FY2017RestatedAnnual report

    「If the prices of raw materials used in the manufacture and sale of the Group's APIs and formulations, or of APIs and other products procured for resale, fluctuate sharply due to exchange rates or other factors, the Group's business performance and financial position may be affected.」

    Reiterates the risk of sharp fluctuations in raw-material and procurement prices and exchange rates.
  15. FY2016First statedAnnual report

    「If the prices of raw materials used in the manufacture and sale of the Group's APIs and formulations, or of APIs and other products procured for resale, fluctuate sharply due to exchange rates or other factors」

    It notes the possibility that fluctuations in raw-material prices and exchange rates may affect business performance and financial position.
Moved together

"Reducing the interest-bearing debt ratio and strengthening equity capital" moved the same way as this thread, in the same document, in 10 of its 20 moves.

1097665★123456
  1. ★This thread
  2. 1Reducing the interest-bearing debt ratio and strengthening equity capital10×
  3. 2Risks Related to Interest-Bearing Debt, Interest Rates and Financial Covenants9×
  4. 3Sales of New Health Food Products and Related Items7×
  5. 4Quality and Stable-Supply Issues Surrounding Imported APIs6×
  6. 5Customer Credit Risk6×
  7. 6Risks from drug price revisions and healthcare insurance system reforms5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet. It last moved in the Earnings of 2026-10-14: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of fluctuations in raw-material and procurement prices | Daito Pharmaceutical Co.,Ltd. (4577) | Komori